Get the Stockscreener App
4.175
0.12%
0.005
Pre-market:
4.17
-0.005
-0.12%
Adverum Biotechnologies Inc stock is traded at $4.175, with a volume of 1.32M.
It is up +0.12% in the last 24 hours and down -3.36% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$4.17
Open:
$4.17
24h Volume:
1.32M
Relative Volume:
1.97
Market Cap:
$92.17M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.6947
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
+0.36%
1M Performance:
-3.36%
6M Performance:
+69.03%
1Y Performance:
-30.42%
1-Day Range:
$4.17
$4.24
1-Week Range:
$4.07
$4.24
52-Week Range:
$1.78
$6.12
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.175 | 92.06M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Sells 51,961 Shares - MarketBeat
Adverum Biotechnologies Releases Promising Phase 2 Trial Data - TipRanks
Adverum Biotechnologies, Inc. Announces Two-Year Data from LUNA Phase 2 Trial - TradingView
How Adverum Biotechnologies Inc. (AVU0) stock reacts to stronger dollarJuly 2025 Highlights & Growth Oriented Trade Recommendations - Newser
Why Adverum Biotechnologies Inc. (AVU0) stock trades below fair valueMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Is Adverum Biotechnologies Inc. (AVU0) stock resilient in recession scenariosQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Is Adverum Biotechnologies Inc. (AVU0) stock undervalued by metricsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Published on: 2025-12-02 05:06:35 - Newser
What technical patterns form on Adverum Biotechnologies Inc. (AVU0) stock charts - Newser
Will Adverum Biotechnologies Inc. (AVU0) stock return to pre crash levelsMarket Growth Review & Consistent Profit Trading Strategies - Newser
Why retail traders accumulate Adverum Biotechnologies Inc. (AVU0) stock2025 Volume Leaders & Fast Gain Swing Trade Alerts - Newser
How Adverum Biotechnologies Inc. (AVU0) stock performs in volatility spikesQuarterly Market Review & Precise Trade Entry Recommendations - Newser
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns - Investing.com Canada
Adverum reminds stockholders to tender their shares into the offer by Lilly - marketscreener.com
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnolo - GuruFocus
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns By Investing.com - Investing.com South Africa
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biote - The National Law Review
What analysts say about Adverum Biotechnologies Inc stockSector Performance Review & Free Rapid Portfolio Appreciation - earlytimes.in
Adverum Biotechnologies Faces Lease Termination Notice - TipRanks
Adverum Biotechnologies IncARE-NC Region No. 21 LLC terminates certain lease agreement with Adverum BiotechnologiesSEC filing - MarketScreener
[8-K] Adverum Biotechnologies, Inc. Reports Material Event | ADVM SEC FilingForm 8-K - Stock Titan
Lilly strengthens gene therapy portfolio with MeiraGTx and Adverum deals - Drug Discovery News
Chart overlay techniques for tracking Adverum Biotechnologies Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Is Adverum Biotechnologies Inc. stock cheap compared to fundamentals2025 Retail Activity & Weekly High Momentum Picks - newser.com
Why Adverum Biotechnologies Inc. stock remains on watchlistsJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Adverum Biotechnologies (ADVM) Price Target Decreased by 11.61% to 10.10 - MSN
Will Adverum Biotechnologies Inc. stock maintain growth storyMarket Growth Report & Safe Swing Trade Setups - newser.com
Has Adverum Biotechnologies Inc. found a price floor2025 Risk Factors & Low Risk High Reward Ideas - newser.com
Volume spikes in Adverum Biotechnologies Inc. stock – what they mean2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Will Adverum Biotechnologies Inc. (AVU0) stock benefit from mergersJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum - sharewise.com
Published on: 2025-11-19 05:22:39 - newser.com
Will Adverum Biotechnologies Inc. stock deliver consistent dividends2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Published on: 2025-11-18 23:52:15 - newser.com
Why analysts maintain buy rating on Adverum Biotechnologies Inc. (AVU0) stockWatch List & Target Return Focused Picks - newser.com
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):